Drugs / Livmoniplimab
Livmoniplimab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06487559 | Sep 2024 → Oct 2027 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT03821935 | Feb 2019 → Jun 2027 expected | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06632951 | Jan 2025 → Mar 2027 expected | urothelial carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05822752 | Sep 2023 → Nov 2026 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06236438 | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06109272 | Jan 2024 → Sep 2030 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-21 | AbbVie | AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target abbvie.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Livmoniplimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06487559 ↗ |
| Known as | ABBV-151 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗ |
| Known as | ARGX-115 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗ |
| Known as | PR-1762844 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗ |
| Action | Inhibit | “Livmoniplimab is a monoclonal antibody (mAb) that binds the GARP:TGF-ß1 complex to inhibit activation and release of TGF-ß1.” PMID 39534099 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “Livmoniplimab is a monoclonal antibody (mAb) that binds the GARP:TGF-ß1 complex to inhibit activation and release of TGF-ß1.” PMID 39534099 ↗ Oct 2024 |
| Route | Intravenous | “Liquid for intravenous infusion.” NCT03821935 ↗ |